Sherbrooke Park Advisers LLC Arrowhead Pharmaceuticals, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $230 Billion
- Q2 2025
A detailed history of Sherbrooke Park Advisers LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 22,712 shares of ARWR stock, worth $960,944. This represents 0.16% of its overall portfolio holdings.
Number of Shares
22,712Holding current value
$960,944% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding ARWR
# of Institutions
328Shares Held
99.8MCall Options Held
444KPut Options Held
568K-
Black Rock Inc. New York, NY15.7MShares$664 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.5MShares$657 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY10.6MShares$448 Million3.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$270 Million0.0% of portfolio
-
Slate Path Capital LP New York, NY5.23MShares$221 Million1.65% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $4.48B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...